bpc 157 ulcerative colitis clinical trial phase ii BPC-157: What It Is, What We Know, and Why Its Use for Arthritis Remains Unproven JPP No 5/2013 article 09

It also makes precise, independent dosage adjustments impossible

Without validated biomarkers of efficacy, real-world results remain anecdotal at best

Officially, the FDA cites: Insufficient large-scale clinical trials Concerns about consistency, sourcing, and manufacturing standards The need to meet formal drug approval requirements Critics argue (fairly) that this system: Favors large pharmaceutical companies Makes it hard to approve naturally occurring peptides Leaves promising, low-risk compounds in regulatory limbo The short version: This FDA restrictive regulatory change of mind wasnt driven by a sudden safety scare, it was driven by regulatory process and economics

Sleep and circadian restoration Researchers specifically targeting sleep improvement might emphasize bedtime administration and potentially start with lower doses to assess individual sensitivity to melatonin-related effects

Consider including funds or ETFs that track both developed and emerging markets for broader global coverage